Dr. Michael Gollob
Scientist, Toronto General Research Institute | University Health Network
Toronto, ON, CANADA
Dr. Gollob specializes in molecular medicine
Media
Publications:
Documents:
Videos:
Audio/Podcasts:
Biography
The Peter Munk Cardiac Centre (PMCC) is home to Michael Gollob's, the Chair of the Centre of Excellence in Molecular Medicine. In this role, Dr. Gollob, who joined the Peter Munk Cardiac Centre in September 2014, will ensure that the PMCC further advances the personalizing of patient care by integrating traditional clinical information, including imaging, with genetic, molecular, cellular and physiological data. The hope is that a better understanding of the molecular signature of a patient's cardiovascular disease, will enable doctors to design, develop and evaluate unique therapies for individual patients with heart failure, valve disease, aortic aneurysms and other cardiovascular diseases.
Industry Expertise (2)
Health and Wellness
Medical Devices
Areas of Expertise (4)
Genetics
Atrial Fibrillation
Mouse Models
Inherited Arrhythmia Syndromes
Accomplishments (1)
Heart and Stroke Foundation of Ontario; Mid-Career Scientist Award (professional)
Presented for achievements in his line of work
Education (2)
University of Toronto: Bachelor of Science, Molecular Genetics
Gold Medallist
University of Toronto: Doctor of Medicine
Media Appearances (2)
Breaking ground: Understanding how the heart is wired
The Toronto Start
2015-02-02
Motivated by the her daughter’s death, Geri Morey raises awareness about sudden cardiac death in the young and the life-saving work at PMCC
PMCC’s acclaimed recruit named Centre of Excellence Chair
UHN
2014-10-15
Dr. Michael Gollob joins the Peter Munk Cardiac Centre Electrophysiology Department and is appointed Chair of the Centre of Excellence in Molecular Medicine.
Articles (3)
Integrating Genetic, Transcriptional, and Functional Analyses to Identify Five Novel Genes for Atrial Fibrillation
American Heart Association Journals
2014 "Background—Atrial fibrillation (AF) affects over 30 million individuals worldwide and is associated with an increased risk of stroke, heart failure, and death. AF is highly heritable, yet the genetic basis for the arrhythmia remains incompletely understood. "
Meta-analysis identifies six new susceptibility loci for atrial fibrillation
Nature Genetics
2012 "Atrial fibrillation is a highly prevalent arrhythmia and a major risk factor for stroke, heart failure and death1. We conducted a genome-wide association study (GWAS) in individuals of European ancestry, including 6,707 with and 52,426 without atrial fibrillation. Six new atrial fibrillation susceptibility loci were identified and replicated in an additional sample of individuals of European ancestry, including 5,381 subjects with and 10,030 subjects without atrial fibrillation (P < 5 × 10−8). Four of the loci identified in Europeans were further replicated in silico in a GWAS of Japanese individuals, including 843 individuals with and 3,350 individuals without atrial fibrillation. The identified loci implicate candidate genes that encode transcription factors related to cardiopulmonary development, cardiac-expressed ion channels and cell signaling molecules."
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
The Lancet
2012 "Background : Prospective assessment of pharmacogenetic strategies has been limited by an inability to undertake bedside genetic testing. The CYP2C19*2 allele is a common genetic variant associated with increased rates of major adverse events in individuals given clopidogrel after percutaneous coronary intervention (PCI). We used a novel point-of-care genetic test to identify carriers of the CYP2C19*2 allele and aimed to assess a pharmacogenetic approach to dual antiplatelet treatment after PCI."